We hypothesized that administration of ACE2 inhibitor MLN-4760 may lead to exacerbation of pre-existing hypertension and/or behavioural abnormalities in SHRs in association with oxidative stress and inflammation. This evidence concerns the gene ACE2 and hypertensive disorder.